Literature DB >> 9062402

Immunoconjugates made of an anti-EGF receptor monoclonal antibody and type 1 ribosome-inactivating proteins from Saponaria ocymoides or Vaccaria pyramidata.

A M Di Massimo1, M Di Loreto, A Pacilli, G Raucci, L D'Alatri, A Mele, A Bolognesi, L Polito, F Stirpe, R De Santis.   

Abstract

The present paper describes two immunoconjugates consisting of an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb), named Mint5, covalently linked to the type 1 ribosome-inactivating proteins (RIPs) ocymoidine (Ocy) and pyramidatine (Pyra) from Saponaria ocymoides and Vaccaria pyramidata respectively. Both antibody and toxins are shown to retain their respective biological properties upon chemical conjugation. The immunoconjugates exert specific inhibition of EGFR expressing target cell proliferation and protein synthesis in in vitro assays and also inhibit the growth of grafted human tumour cells in nude mice.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9062402      PMCID： PMC2063398          DOI： 10.1038/bjc.1997.147

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  20 in total

1.  Immunological properties of ribosome-inactivating proteins and a saporin immunotoxin.

Authors:  P Strocchi; L Barbieri; F Stirpe
Journal:  J Immunol Methods       Date:  1992-10-19       Impact factor: 2.303

Review 2.  Mitotoxins: growth factor-targeted cytotoxic molecules.

Authors:  D A Lappi; A Baird
Journal:  Prog Growth Factor Res       Date:  1990

3.  Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.

Authors:  H Masui; H Kamrath; G Apell; L L Houston; J Mendelsohn
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

Review 4.  Ribosome-inactivating proteins from plants.

Authors:  L Barbieri; M G Battelli; F Stirpe
Journal:  Biochim Biophys Acta       Date:  1993-12-21

Review 5.  The EGF receptor system as a target for antitumor therapy.

Authors:  B W Ennis; M E Lippman; R B Dickson
Journal:  Cancer Invest       Date:  1991       Impact factor: 2.176

6.  Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.

Authors:  J Baselga; L Norton; H Masui; A Pandiella; K Coplan; W H Miller; J Mendelsohn
Journal:  J Natl Cancer Inst       Date:  1993-08-18       Impact factor: 13.506

7.  The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients.

Authors:  S B Fox; K Smith; J Hollyer; M Greenall; D Hastrich; A L Harris
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

8.  Anti-tumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal antibody and its F(ab')2 fragment against high- and low-EGFR-expressing carcinomas in nude mice.

Authors:  E Tosi; O Valota; D R Negri; E Adobati; A Mazzoni; R Meazza; S Ferrini; M I Colnaghi; S Canevari
Journal:  Int J Cancer       Date:  1995-09-04       Impact factor: 7.396

9.  Ribosome-inactivating proteins (RNA N-glycosidases) from the seeds of Saponaria ocymoides and Vaccaria pyramidata.

Authors:  A Bolognesi; F Olivieri; M G Battelli; L Barbieri; A I Falasca; A Parente; F Del Vecchio Blanco; F Stirpe
Journal:  Eur J Biochem       Date:  1995-03-15

Review 10.  Systemic immunotoxin therapy of cancer: advances and prospects.

Authors:  E J Wawrzynczak
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640
View more
  11 in total

1.  Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.

Authors:  Christopher M Pirie; Benjamin J Hackel; Michael G Rosenblum; K Dane Wittrup
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

2.  Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001).

Authors:  N G Rainov; V Heidecke
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

3.  Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma.

Authors:  Friedrich Weber; Anthony Asher; Richard Bucholz; Mitchel Berger; Michael Prados; Susan Chang; Jeffrey Bruce; Walter Hall; Nikolai G Rainov; Manfred Westphal; Ronald E Warnick; Robert W Rand; Frank Floeth; Frank Rommel; Henry Pan; Vijay N Hingorani; Raj K Puri
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

Review 4.  Ribosome-inactivating and related proteins.

Authors:  Joachim Schrot; Alexander Weng; Matthias F Melzig
Journal:  Toxins (Basel)       Date:  2015-05-08       Impact factor: 4.546

Review 5.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 6.  Plant Toxin-Based Immunotoxins for Cancer Therapy: A Short Overview.

Authors:  Letizia Polito; Alice Djemil; Massimo Bortolotti
Journal:  Biomedicines       Date:  2016-06-01

Review 7.  Bouganin, an Attractive Weapon for Immunotoxins.

Authors:  Massimo Bortolotti; Andrea Bolognesi; Letizia Polito
Journal:  Toxins (Basel)       Date:  2018-08-08       Impact factor: 4.546

Review 8.  Hyperuricaemia, Xanthine Oxidoreductase and Ribosome-Inactivating Proteins from Plants: The Contributions of Fiorenzo Stirpe to Frontline Research.

Authors:  Andrea Bolognesi; Massimo Bortolotti; Maria Giulia Battelli; Letizia Polito
Journal:  Molecules       Date:  2017-01-27       Impact factor: 4.411

Review 9.  The Updated Review on Plant Peptides and Their Applications in Human Health.

Authors:  Saiprahalad Mani; Smruti B Bhatt; Vinduja Vasudevan; Dhamodharan Prabhu; Sundararaj Rajamanikandan; Palaniyandi Velusamy; Palaniappan Ramasamy; Pachaiappan Raman
Journal:  Int J Pept Res Ther       Date:  2022-07-27       Impact factor: 2.191

10.  Synergistic antitumor activity from two-stage delivery of targeted toxins and endosome-disrupting nanoparticles.

Authors:  Xingfang Su; Nicole Yang; K Dane Wittrup; Darrell J Irvine
Journal:  Biomacromolecules       Date:  2013-03-11       Impact factor: 6.988
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.